Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment

Diabetes Research and Clinical Practice

Volumn 135, Issue , 2018, Pages 178-184

  Horie, Ichiro ^a   Abiru, Norio ^a   Hongo, Ryoko ^a   Nakamura, Takeshi ^a   Ito, Ayako ^a   Haraguchi, Ai ^a   Natsuda, Shoko ^a   Sagara, Ikuko ^a   Ando, Takao ^a   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

BDHQ; Dapagliflozin; Diet history; Hyperphagia; SGLT2; Sugar

Indexed keywords

DAPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; CARBOHYDRATE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BRIEF TYPE SELF ADMINISTERED DIET HISTORY QUESTIONNAIRE; CALORIC INTAKE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENDER; HUMAN; HYPERPHAGIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; SUGAR INTAKE; TREATMENT OUTCOME; ADOLESCENT; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; FEMALE; GLUCOSIDES; HUMANS; HYPERPHAGIA; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS; SUGARS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85036535429     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.11.016     Document Type: Article

References (30)

1. Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
2. Chao, E.C., Henry, R.R., SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discovery 9 (2010), 551–559.
3. Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K.D., Ferrannini, E., Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1730–1735.
4. Polidori, D., Sanghvi, A., Seeley, R.J., Hall, K.D., How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring) 24 (2016), 2289–2295.
5. Devenny, J.J., Godonis, H.E., Harvey, S.J., Rooney, S., Cullen, M.J., Pelleymounter, M.A., Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20 (2012), 1645–1652.
6. Kobayashi, S., Murakami, K., Sasaki, S., Okubo, H., Hirota, N., Notsu, A., et al. Comparison of relative validity of food group intakes estimated by comprehensive and brief-type self-administered diet history questionnaires against 16 d dietary records in Japanese adults. Public Health Nutr 14 (2011), 1200–1211.
7. Kobayashi, S., Honda, S., Murakami, K., Sasaki, S., Okubo, H., Hirota, N., et al. Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol 22 (2012), 151–159.
8. Sasaki, S., Yanagibori, R., Amano, K., Self-administered diet history questionnaire developed for health education: a relative validation of the test-version by comparison with 3-day diet record in women. J Epidemiol 8 (1998), 203–215.
9. Sasaki, S., Yanagibori, R., Amano, K., Validity of a self-administered diet history questionnaire for assessment of sodium and potassium: comparison with single 24-hour urinary excretion. Jpn Circ J 62 (1998), 431–435.
10. Sasaki, S., Ushio, F., Amano, K., Morihara, M., Todoriki, O., Uehara, Y., et al. Serum biomarker-based validation of a self-administered diet history questionnaire for Japanese subjects. J Nutr Sci Vitaminol (Tokyo) 46 (2000), 285–296.
11. Okubo, H., Sasaki, S., Rafamantanantsoa, H.H., Ishikawa-Takata, K., Okazaki, H., Tabata, I., Validation of self-reported energy intake by a self-administered diet history questionnaire using the doubly labeled water method in 140 Japanese adults. Eur J Clin Nutr 62 (2008), 1343–1350.
12. Miyake, Y., Sasaki, S., Tanaka, K., Ohfuji, S., Hirota, Y., Maternal fat consumption during pregnancy and risk of wheeze and eczema in Japanese infants aged 16–24 months: the Osaka Maternal and Child Health Study. Thorax 64 (2009), 815–821.
13. Ohta, H., Kuroda, T., Onoe, Y., Orito, S., Ohara, M., Kume, M., et al. The impact of lifestyle factors on serum 25-hydroxyvitamin D levels: a cross-sectional study in Japanese women aged 19–25 years. J Bone Miner Metab 27 (2009), 682–688.
14. Murakami, K., Sasaki, S., Takahashi, Y., Uenishi, K., Yamasaki, M., Hayabuchi, H., et al. Hardness (difficulty of chewing) of the habitual diet in relation to body mass index and waist circumference in free-living Japanese women aged 18–22 y. Am J Clin Nutr 86 (2007), 206–213.
15. Okubo, H., Sasaki, S., Horiguchi, H., Oguma, E., Miyamoto, K., Hosoi, Y., et al. Dietary patterns associated with bone mineral density in premenopausal Japanese farmwomen. Am J Clin Nutr 83 (2006), 1185–1192.
16. Sakata, S., Tsuchihashi, T., Oniki, H., Tominaga, M., Arakawa, K., Sakaki, M., et al. Relationship between salt intake as estimated by a brief self-administered diet-history questionnaire (BDHQ) and 24-h urinary salt excretion in hypertensive patients. Hypertens Res 38 (2015), 560–563.
17. Polidori, D., Mari, A., Ferrannini, E., Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57 (2014), 891–901.
18. Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS ONE, 11, 2016, e0151511.
19. Tatarkiewicz, K., Polizzi, C., Villescaz, C., D'Souza, L.J., Wang, Y., Janssen, S., et al. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. Diabetes Obes Metab 16 (2014), 376–380.
20. Sakai, S., Kaku, K., Seino, Y., Inagaki, N., Haneda, M., Sasaki, T., et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther, 38(843–62), 2016, e9.
21. Kashiwagi, A., Yoshida, S., Nakamura, I., Kazuta, K., Ueyama, E., Takahashi, H., et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig 7 (2016), 544–554.
22. Leiter, L.A., Forst, T., Polidori, D., Balis, D.A., Xie, J., Sha, S., Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42 (2016), 25–32.
23. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med 373 (2015), 2117–2128.
24. Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
25. Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
26. Perkins, B.A., Cherney, D.Z., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
27. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. DiabetesObesity Metab 2017.
28. Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124 (2014), 509–514.
29. DeFronzo, R.A., Norton, L., Abdul-Ghani, M., Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13 (2017), 11–26.
30. Wright, E.M., Loo, D.D., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol Rev 91 (2011), 733–794.